In this volume, a team of internationally recognized experts provide an in-depth description of therapeutic biomarkers across a broad area of cancer research and oncology. With a wealth of information to specific therapies, each chapter focuses on a class of targeted chemotherapy agents. The book describes established and evolving diagnostic tests for therapeutic biomarkers that predict benefit, response, resistance, or drug side effects from specific therapeutic interventions. This volume is an essential handbook for health professionals and scientists researching current applicable biomarkers in oncology.
Overview: Therapeutic Biomarkers in Cancer, Sherry X. Yang and Janet E. Dancey Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer, Lisa M. McShane, Edward L. Korn and Boris Freidlin Role of Biomarkers in Clinical Development of New Cancer Therapies, Helen X. Chen HER2 as a Prognostic and Predictive Biomarker in Cancer, Suparna Wedam and Stan Lipkowitz Hormone Receptors and Endocrine Therapy in Breast Cancer, Chia C. Portera and Sherry X. Yang Predictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung Cancer, John Hilton, Penelope A. Bradbury, and Janet E. Dancey Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer, Jose G. Monzon and Janet E. Dancey Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia, Shamudheen Rafiyath, Guoqing Wei, and Delong Liu Gastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to Therapy, Joaquina Baranda, Rashna Madan and Andrew K. Godwin PML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment, Alicja Gruszka and Myriam Alcalay Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil Toxicity, Eva Gross and Andre B. P. van Kuilenburg UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity, Kellie Reece and William D. Figg The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer, Petra Rietchel and Joseph A. Sparano MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients, Sonal J. Desai and Tianhong Li BRCA mutation and PARP Inhibitors, Marcie K. Weil, Shivaani Kummar, James H. Doroshow, and Alice P. Chen EML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung Cancer, Vimal Patel, MD and Biren Saraiya BRAF-Targeted Therapy in Metastatic Melanoma, Noori Kim and April C. Deng